Evotec AG (Frankfurt Stock Exchange: EVT; NASDAQ: EVTC) announced today the appointment of Dr. Werner Lanthaler as Chief Executive Officer of the Company, effective immediately. In his previous position, Dr. Lanthaler served as Chief Financial Officer of Intercell AG in Vienna, Austria, a global biopharmaceutical leader dedicated to the development of vaccines. In this role, he was also responsible for Business Development and Marketing & Sales.
Dr. Lanthaler had eight very successful years at Intercell AG where he served since 2001. During his tenure, Intercell developed from a venture-backed biotechnology company into a global vaccine player. Dr. Lanthaler played a pivotal role in many of the company’s major corporate milestones including the most recent product approval of Intercell’s Japanese Encephalitis Vaccine, the company’s acquisitions and strategic pharma partnerships, as well as the company’s Initial Public Offering on the Vienna Stock Exchange in 2005.
Previously, Dr. Lanthaler served as Director of the Federation of Austrian Industry and as Senior Management Consultant at the consulting firm McKinsey & Company. He holds a doctorate in economics from Vienna University, earned his Master’s degrees from Harvard University, and holds a degree in Psychology.
Dr. Flemming Ornskov, Chairman of the Supervisory Board of Evotec, stated: “Dr. Lanthaler is an ideal candidate to be CEO of Evotec at this juncture. His experience in building a highly successful company, his impressive track record in business and corporate development, and his strong sense for the creation of shareholder value are a perfect match with Evotec’s strategy to transform itself into a streamlined biopharmaceutical company. In summary, he brings all the skills and experience needed in order to adapt and shape Evotec’s strategy and move the Company to the next level of success.”
“I look forward to joining this exciting company in a challenging market environment. It possesses an abundance of opportunities based on good fundamental science, an excellent reputation for drug discovery and development, and strong financial resources. It is my goal to advance Evotec’s vision and generate significant shareholder value in the years to come”, stated Dr. Werner Lanthaler, the Chief Executive Officer of Evotec.
Evotec is a leader in the discovery and development of novel small molecule drugs. Both through its own discovery programs and through its research collaborations, Evotec is generating high quality results for its many partners in the pharmaceutical and biotechnology industries. In its proprietary projects, Evotec specializes in finding new treatments for diseases of the nervous system. Evotec’s portfolio comprises five clinical compounds: EVT 101, a subtype selective NMDA receptor antagonist with potential for the treatment of Alzheimer’s disease, pain and depression; EVT 201, a partial positive allosteric modulator (pPAM) of the GABAA receptor complex for the treatment of insomnia; EVT 302, a MAO-B inhibitor in development for smoking cessation; a P2X7 antagonist for the treatment of inflammatory diseases; and a vanilloid receptor (VR1) antagonists for the treatment of pain in partnership with Pfizer.
In addition, Evotec has a number of proprietary projects in preclinical development.
For information on Evotec, please be invited to our website at www.evotec.com